Diagnostic  ||| S:0 E:11 ||| NNP
Values  ||| S:11 E:18 ||| NNP
of  ||| S:18 E:21 ||| IN
Carcinoembryonic  ||| S:21 E:38 ||| NNP
Antigen ||| S:38 E:45 ||| NNP
,  ||| S:45 E:47 ||| ,
Cancer  ||| S:47 E:54 ||| NNP
Antigen  ||| S:54 E:62 ||| NNP
15-3  ||| S:62 E:67 ||| NNP
and  ||| S:67 E:71 ||| CC
Cancer  ||| S:71 E:78 ||| NNP
Antigen  ||| S:78 E:86 ||| NNP
125  ||| S:86 E:90 ||| CD
Levels  ||| S:90 E:97 ||| NNS
in  ||| S:97 E:100 ||| IN
Nipple  ||| S:100 E:107 ||| NNP
Discharge  ||| S:107 E:117 ||| NNP
An  ||| S:117 E:120 ||| DT
expedient  ||| S:120 E:130 ||| NN
and  ||| S:130 E:134 ||| CC
cost-effective  ||| S:134 E:149 ||| JJ
diagnostic  ||| S:149 E:160 ||| JJ
tool  ||| S:160 E:165 ||| NN
is  ||| S:165 E:168 ||| VBZ
needed  ||| S:168 E:175 ||| VBN
to  ||| S:175 E:178 ||| TO
complement  ||| S:178 E:189 ||| VB
galactography  ||| S:189 E:203 ||| NNS
and  ||| S:203 E:207 ||| CC
exfoliative  ||| S:207 E:219 ||| JJ
cytology  ||| S:219 E:228 ||| NN
for  ||| S:228 E:232 ||| IN
detection  ||| S:232 E:242 ||| NN
of  ||| S:242 E:245 ||| IN
benign  ||| S:245 E:252 ||| JJ
or  ||| S:252 E:255 ||| CC
malignant  ||| S:255 E:265 ||| JJ
breast  ||| S:265 E:272 ||| NN
diseases  ||| S:272 E:281 ||| NNS
with  ||| S:281 E:286 ||| IN
nipple  ||| S:286 E:293 ||| JJ
discharge ||| S:293 E:302 ||| NN
.  ||| S:302 E:304 ||| .
The  ||| S:304 E:308 ||| DT
aim  ||| S:308 E:312 ||| NN
of  ||| S:312 E:315 ||| IN
this  ||| S:315 E:320 ||| DT
prospective  ||| S:320 E:332 ||| JJ
study  ||| S:332 E:338 ||| NN
is  ||| S:338 E:341 ||| VBZ
to  ||| S:341 E:344 ||| TO
explore  ||| S:344 E:352 ||| VB
the  ||| S:352 E:356 ||| DT
utility  ||| S:356 E:364 ||| NN
of  ||| S:364 E:367 ||| IN
carcinoembryonic  ||| S:367 E:384 ||| JJ
antigen ||| S:384 E:391 ||| NN
,  ||| S:391 E:393 ||| ,
cancer  ||| S:393 E:400 ||| NN
antigen  ||| S:400 E:408 ||| NN
15-3  ||| S:408 E:413 ||| NN
and  ||| S:413 E:417 ||| CC
cancer  ||| S:417 E:424 ||| NN
antigen  ||| S:424 E:432 ||| VBD
125  ||| S:432 E:436 ||| CD
levels  ||| S:436 E:443 ||| NNS
in  ||| S:443 E:446 ||| IN
nipple  ||| S:446 E:453 ||| JJ
discharge  ||| S:453 E:463 ||| NN
for  ||| S:463 E:467 ||| IN
the  ||| S:467 E:471 ||| DT
diagnosis  ||| S:471 E:481 ||| NN
of  ||| S:481 E:484 ||| IN
various  ||| S:484 E:492 ||| JJ
breast  ||| S:492 E:499 ||| NN
diseases ||| S:499 E:507 ||| NNS
.  ||| S:507 E:509 ||| .
We  ||| S:509 E:512 ||| PRP
evaluated  ||| S:512 E:522 ||| VBD
the  ||| S:522 E:526 ||| DT
pre-operative  ||| S:526 E:540 ||| JJ
tumor  ||| S:540 E:546 ||| NN
marker  ||| S:546 E:553 ||| NN
levels  ||| S:553 E:560 ||| NNS
in  ||| S:560 E:563 ||| IN
153  ||| S:563 E:567 ||| CD
nipple  ||| S:567 E:574 ||| JJ
discharge  ||| S:574 E:584 ||| NN
samples  ||| S:584 E:592 ||| NNS
collected  ||| S:592 E:602 ||| VBN
from  ||| S:602 E:607 ||| IN
one  ||| S:607 E:611 ||| CD
or  ||| S:611 E:614 ||| CC
both  ||| S:614 E:619 ||| DT
breasts  ||| S:619 E:627 ||| NN
of  ||| S:627 E:630 ||| IN
142  ||| S:630 E:634 ||| CD
women  ||| S:634 E:640 ||| NNS
undergoing  ||| S:640 E:651 ||| VBG
surgery ||| S:651 E:658 ||| NN
.  ||| S:658 E:660 ||| .
Patients  ||| S:660 E:669 ||| NNS
with  ||| S:669 E:674 ||| IN
nipple  ||| S:674 E:681 ||| JJ
discharge  ||| S:681 E:691 ||| NN
underwent  ||| S:691 E:701 ||| VBD
auxiliary  ||| S:701 E:711 ||| JJ
examination  ||| S:711 E:723 ||| NN
( ||| S:723 E:724 ||| -LRB-
ultrasonography ||| S:724 E:739 ||| UH
,  ||| S:739 E:741 ||| ,
exfoliative  ||| S:741 E:753 ||| JJ
cytology ||| S:753 E:761 ||| NN
,  ||| S:761 E:763 ||| ,
ductoscopy  ||| S:763 E:774 ||| NN
and  ||| S:774 E:778 ||| CC
galactography ||| S:778 E:791 ||| CD
) ||| S:791 E:792 ||| -RRB-
.  ||| S:792 E:794 ||| .
Statistically  ||| S:794 E:808 ||| RB
higher  ||| S:808 E:815 ||| JJR
levels  ||| S:815 E:822 ||| NNS
of  ||| S:822 E:825 ||| IN
carcinoembryonic  ||| S:825 E:842 ||| JJ
antigen  ||| S:842 E:850 ||| NN
and  ||| S:850 E:854 ||| CC
cancer  ||| S:854 E:861 ||| NN
antigen  ||| S:861 E:869 ||| NN
15-3  ||| S:869 E:874 ||| NN
were  ||| S:874 E:879 ||| VBD
found  ||| S:879 E:885 ||| VBN
in  ||| S:885 E:888 ||| IN
patients  ||| S:888 E:897 ||| NNS
in  ||| S:897 E:900 ||| IN
the  ||| S:900 E:904 ||| DT
malignant  ||| S:904 E:914 ||| JJ
group  ||| S:914 E:920 ||| NN
as  ||| S:920 E:923 ||| IN
compared  ||| S:923 E:932 ||| VBN
to  ||| S:932 E:935 ||| TO
those  ||| S:935 E:941 ||| DT
in  ||| S:941 E:944 ||| IN
the  ||| S:944 E:948 ||| DT
benign  ||| S:948 E:955 ||| JJ
group ||| S:955 E:960 ||| NN
.  ||| S:960 E:962 ||| .
No  ||| S:962 E:965 ||| DT
statistically  ||| S:965 E:979 ||| JJ
significant  ||| S:979 E:991 ||| JJ
difference  ||| S:991 E:1002 ||| NN
in  ||| S:1002 E:1005 ||| IN
the  ||| S:1005 E:1009 ||| DT
level  ||| S:1009 E:1015 ||| NN
of  ||| S:1015 E:1018 ||| IN
cancer  ||| S:1018 E:1025 ||| NN
antigen  ||| S:1025 E:1033 ||| VBD
125  ||| S:1033 E:1037 ||| CD
( ||| S:1037 E:1038 ||| -LRB-
P  ||| S:1038 E:1040 ||| NN
=  ||| S:1040 E:1042 ||| SYM
0.895 ||| S:1042 E:1047 ||| CD
) ||| S:1047 E:1048 ||| -RRB-
.  ||| S:1048 E:1050 ||| .
Sensitivities  ||| S:1050 E:1064 ||| NNS
of  ||| S:1064 E:1067 ||| IN
carcinoembryonic  ||| S:1067 E:1084 ||| JJ
antigen  ||| S:1084 E:1092 ||| NN
and  ||| S:1092 E:1096 ||| CC
cancer  ||| S:1096 E:1103 ||| NN
antigen  ||| S:1103 E:1111 ||| NN
15-3  ||| S:1111 E:1116 ||| NN
for  ||| S:1116 E:1120 ||| IN
diagnosing  ||| S:1120 E:1131 ||| JJ
breast  ||| S:1131 E:1138 ||| NN
cancer  ||| S:1138 E:1145 ||| NN
were  ||| S:1145 E:1150 ||| VBD
74.42 ||| S:1150 E:1155 ||| CD
%  ||| S:1155 E:1157 ||| NN
and  ||| S:1157 E:1161 ||| CC
58.14 ||| S:1161 E:1166 ||| CD
% ||| S:1166 E:1167 ||| NN
,  ||| S:1167 E:1169 ||| ,
and  ||| S:1169 E:1173 ||| CC
specificities  ||| S:1173 E:1187 ||| NNS
were  ||| S:1187 E:1192 ||| VBD
87.27 ||| S:1192 E:1197 ||| CD
%  ||| S:1197 E:1199 ||| NN
and  ||| S:1199 E:1203 ||| CC
80.00 ||| S:1203 E:1208 ||| CD
%  ||| S:1208 E:1210 ||| NN
where  ||| S:1210 E:1216 ||| WRB
as  ||| S:1216 E:1219 ||| IN
the  ||| S:1219 E:1223 ||| DT
cutoff  ||| S:1223 E:1230 ||| JJ
values  ||| S:1230 E:1237 ||| NNS
with  ||| S:1237 E:1242 ||| IN
max-sum  ||| S:1242 E:1250 ||| JJ
of  ||| S:1250 E:1253 ||| IN
sensitivity  ||| S:1253 E:1265 ||| NN
and  ||| S:1265 E:1269 ||| CC
specificity  ||| S:1269 E:1281 ||| NN
were  ||| S:1281 E:1286 ||| VBD
224.3  ||| S:1286 E:1292 ||| CD
ng ||| S:1292 E:1294 ||| CD
/ ||| S:1294 E:1295 ||| CD
ml  ||| S:1295 E:1298 ||| NNS
and  ||| S:1298 E:1302 ||| CC
1368.2  ||| S:1302 E:1309 ||| NNP
U ||| S:1309 E:1310 ||| NNP
/ ||| S:1310 E:1311 ||| NNP
ml ||| S:1311 E:1313 ||| NN
,  ||| S:1313 E:1315 ||| ,
respectively ||| S:1315 E:1327 ||| RB
.  ||| S:1327 E:1329 ||| .
The  ||| S:1329 E:1333 ||| DT
following  ||| S:1333 E:1343 ||| JJ
sensitivities  ||| S:1343 E:1357 ||| NNS
for  ||| S:1357 E:1361 ||| IN
telling  ||| S:1361 E:1369 ||| VBG
malignant  ||| S:1369 E:1379 ||| JJ
from  ||| S:1379 E:1384 ||| IN
benign  ||| S:1384 E:1391 ||| NNS
could  ||| S:1391 E:1397 ||| MD
be  ||| S:1397 E:1400 ||| VB
determined ||| S:1400 E:1410 ||| VBN
:  ||| S:1410 E:1412 ||| :
exfoliative  ||| S:1412 E:1424 ||| CD
cytology  ||| S:1424 E:1433 ||| CD
46.67 ||| S:1433 E:1438 ||| CD
% ||| S:1438 E:1439 ||| NN
,  ||| S:1439 E:1441 ||| ,
ultrasonography  ||| S:1441 E:1457 ||| CD
76.74 ||| S:1457 E:1462 ||| CD
% ||| S:1462 E:1463 ||| NN
,  ||| S:1463 E:1465 ||| ,
galactography  ||| S:1465 E:1479 ||| CD
75.00 ||| S:1479 E:1484 ||| CD
% ||| S:1484 E:1485 ||| NN
,  ||| S:1485 E:1487 ||| ,
and  ||| S:1487 E:1491 ||| CC
ductoscopy  ||| S:1491 E:1502 ||| CD
0 ||| S:1502 E:1503 ||| CD
% ||| S:1503 E:1504 ||| NN
.  ||| S:1504 E:1506 ||| .
Exfoliative  ||| S:1506 E:1518 ||| JJ
cytology  ||| S:1518 E:1527 ||| NN
was  ||| S:1527 E:1531 ||| VBD
found  ||| S:1531 E:1537 ||| VBN
to  ||| S:1537 E:1540 ||| TO
be  ||| S:1540 E:1543 ||| VB
a  ||| S:1543 E:1545 ||| DT
valuable  ||| S:1545 E:1554 ||| JJ
alternative  ||| S:1554 E:1566 ||| NN
method  ||| S:1566 E:1573 ||| NN
for  ||| S:1573 E:1577 ||| IN
differentiating  ||| S:1577 E:1593 ||| VBG
benign  ||| S:1593 E:1600 ||| JJ
from  ||| S:1600 E:1605 ||| IN
malignancy ||| S:1605 E:1615 ||| NN
.  ||| S:1615 E:1617 ||| .
Thus ||| S:1617 E:1621 ||| RB
,  ||| S:1621 E:1623 ||| ,
tumor  ||| S:1623 E:1629 ||| NN
marker  ||| S:1629 E:1636 ||| NN
analysis  ||| S:1636 E:1645 ||| NN
of  ||| S:1645 E:1648 ||| IN
nipple  ||| S:1648 E:1655 ||| JJ
discharge  ||| S:1655 E:1665 ||| NN
fluid  ||| S:1665 E:1671 ||| NN
for  ||| S:1671 E:1675 ||| IN
carcinoembryonic  ||| S:1675 E:1692 ||| JJ
antigen  ||| S:1692 E:1700 ||| NN
and  ||| S:1700 E:1704 ||| CC
cancer  ||| S:1704 E:1711 ||| NN
antigen  ||| S:1711 E:1719 ||| NN
15-3  ||| S:1719 E:1724 ||| NN
would  ||| S:1724 E:1730 ||| MD
enhance  ||| S:1730 E:1738 ||| VB
the  ||| S:1738 E:1742 ||| DT
accurate  ||| S:1742 E:1751 ||| JJ
assessment  ||| S:1751 E:1762 ||| NN
and  ||| S:1762 E:1766 ||| CC
treatment  ||| S:1766 E:1776 ||| NN
planning  ||| S:1776 E:1785 ||| NN
for  ||| S:1785 E:1789 ||| IN
patients  ||| S:1789 E:1798 ||| NNS
with  ||| S:1798 E:1803 ||| IN
nipple  ||| S:1803 E:1810 ||| JJ
discharge ||| S:1810 E:1819 ||| NN
.  ||| S:1819 E:1821 ||| .
